Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongfang Liu

Showing results (291-300 of 302) with videos related to

Pageof 31
Sort By:
Cancer Cell|January 16, 2026
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunityJianan Li, Huilan Liu, Qile Guo, et al.
Molecular Cancer Therapeutics|September 16, 2008
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapiesSonya D Zabludoff, Chun Deng, Michael R Grondine, et al.
Nature Immunology|June 12, 2012
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infectionHuabiao Chen, Zaza M Ndhlovu, Dongfang Liu, et al.
Expert Review of Vaccines|January 21, 2025
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variantsGuiqiang Wang, Kexin Zhao, Xiuli Zhao, et al.
The New England Journal of Medicine|December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe AsthmaLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Cell Research|July 8, 2017
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte functionYoung-Hee Lee, Natalia Martin-Orozco, Peilin Zheng, et al.
Nature Communications|July 24, 2024
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trialRuizhi Zhang, Junshi Zhao, Xiaoping Zhu, et al.
Nature Medicine|April 23, 2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNathan Singh, Noelle V Frey, Boris Engels, et al.
Nature Immunology|June 3, 2024
The BTLA-HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Pageof 31

Showing results (291-300 of 302) with videos related to

Sort By:
Pageof 31
Cancer Cell|January 16, 2026
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunityJianan Li, Huilan Liu, Qile Guo, et al.
Molecular Cancer Therapeutics|September 16, 2008
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapiesSonya D Zabludoff, Chun Deng, Michael R Grondine, et al.
Nature Immunology|June 12, 2012
TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infectionHuabiao Chen, Zaza M Ndhlovu, Dongfang Liu, et al.
Expert Review of Vaccines|January 21, 2025
Sustained immunogenicity of bivalent protein COVID-19 vaccine SCTV01C against antigen matched and mismatched variantsGuiqiang Wang, Kexin Zhao, Xiuli Zhao, et al.
The New England Journal of Medicine|December 8, 2021
Dupilumab in Children with Uncontrolled Moderate-to-Severe AsthmaLeonard B Bacharier, Jorge F Maspero, Constance H Katelaris, et al.
Cell Research|July 8, 2017
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte functionYoung-Hee Lee, Natalia Martin-Orozco, Peilin Zheng, et al.
Nature Communications|July 24, 2024
Efficacy of the tetravalent protein COVID-19 vaccine, SCTV01E: a phase 3 double-blind, randomized, placebo-controlled trialRuizhi Zhang, Junshi Zhao, Xiaoping Zhu, et al.
Nature Medicine|April 23, 2021
Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cellsNathan Singh, Noelle V Frey, Boris Engels, et al.
Nature Immunology|June 3, 2024
The BTLA-HVEM axis restricts CAR T cell efficacy in cancerPuneeth Guruprasad, Alberto Carturan, Yunlin Zhang, et al.
Blood|January 6, 2026
Harnessing the CD2 axis to broaden and enhance the efficacy of CAR T-cell therapiesAlberto Carturan, Mathew G Angelos, Puneeth Guruprasad, et al.
Pageof 31